Search Results | MSF Science Portal

Journal Article

|

Pre-Print

Romo ML, LaHood A, Stagg HR, Mitnick CD, Trevisi L, et al.

2025-08-24 • medRxiv

People who smoke are at increased risk of unfavorable tuberculosis (TB) treatment outcomes compared with tho...

Journal Article

|

Research

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S, et al.

2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

Journal Article

|

Research

Sauer SM, Mitnick CD, Khan UT, Hewison CCH, Bastard M, et al.

2024-01-25 • Clinical Infectious Diseases

BACKGROUND
Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...

Journal Article

|

Short Report

Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed SM, Algozhin Y, et al.

2024-01-25 • Clinical Infectious Diseases

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of ...

Journal Article

|

Research

Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD, et al.

2024-01-20 • medRxiv

RATIONALE

Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...

Journal Article

|

Research

Trevisi L, Hernán MA, Mitnick CD, Khan UT, Seung KJ, et al.

2023-06-01 • American Journal of Respiratory and Critical Care Medicine

RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...

Journal Article

|

Research

Rich ML, Khan UT, Zeng C, LaHood AN, Franke MF, et al.

2023-06-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.

OB...

Journal Article

|

Research

Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M, et al.

2023-04-28 • PLOS Global Public Health

Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb tr...

Journal Article

|

Research

Gunasekera KS, Marcy O, Muñoz J, Lopez-Varela E, Sekadde MP, et al.

2023-03-13 • Lancet Child and Adolescent Health

BACKGROUND
Many children with pulmonary tuberculosis remain undiagnosed and untreated with related high morbidity and mortality. Recent advances in childhood tuberculosis algorithm d...

Journal Article

|

Research

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY, et al.

2023-01-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...

Journal Article

|

Research

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, et al.

2020-07-11 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observati...

Journal Article

|

Short Report

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S, et al.

2019-11-02 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...

Research & Publication Resources

|

Research Protocol

Smith SL, Misago CN, Osrow RA, Franke MF, Iyamuremye JD, et al.

2017-02-01 • BMJ Open

Integrating mental healthcare into primary care can reduce the global burden of mental disorders. Yet data on the effective implementation of real-world task-shared mental health program...

Journal Article

|

Commentary

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M, et al.

2020-10-01 • International Journal of Tuberculosis and Lung Disease

In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...

Journal Article

|

Research

Franke MF, Khan P, Hewison C, Khan U, Huerga H, et al.

2021-01-01 • American Journal of Respiratory and Critical Care Medicine

RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...

Journal Article

|

Research

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N, et al.

2022-10-15 • Clinical Infectious Diseases

BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...

Journal Article

|

Letter

Seung KJ, Franke MF, Hewison CCH, Huerga H, Khan UT, et al.

2020-05-01 • Journal of Hepatology

Research & Publication Resources

|

Research Protocol

Khan UT, Huerga H, Khan AS, Mitnick CD, Hewison CCH, et al.

2019-08-20 • BMC Infectious Diseases

BACKGROUND
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...

Journal Article

|

Research

Franke MF, Khan PY, Hewison CCH, Khan UT, Huerga H, et al.

2020-07-24 • American Journal of Respiratory and Critical Care Medicine

BACKGROUND
Bedaquiline and delamanid offer the possibility of more effective and less toxic multidrug-resistant tuberculosis (MDR-TB) treatment. With this treatment, however, some pa...

Journal Article

|

Research

Rodriguez CA, Lodi S, Horsburgh CR, Bastard M, Hewison C, et al.

2022-11-10 • PLOS One

Science Portal

Effect of smoking on drug-resistant tuberculosis treatment outcomes and exploring potential pathways: A multicountry cohort study

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up

Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs

Effectiveness of a bedaquiline, linezolid, clofazimine “core” for multidrug-resistant tuberculosis

Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective

Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Evaluating process and clinical outcomes of a primary care mental health integration project in rural Rwanda: a prospective mixed-methods protocol

Introducing new and repurposed TB drugs: the endTB experience

Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

Culture conversion in patients treated with bedaquiline and/or delamanid: A prospective multi-country study

Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion

BACKGROUND